Endometrial Immune Profile Changes After Autologous Intrauterine PRP Treatment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorNadezhda Women's Health Hospital
About this trial
The success rate after treatment by in-vitro fertilisation (IVF) strongly depends on the endometrial receptivity, which in turn is strictly connected to the endometrial immune profile. IVF outcome is largely dependent upon endometrial immune cell ratios and their relationship with one another.
During the last few years there are several studies and case reports for intrauterine PRP application in patients resulting in a thicker, regenerated endometrium and better immune cell population ratios.
In this project, the investigators aim to analyze the effect of autologous intrauterine PRP administration on the endometrial immune profile, endometrial thickness, selected hormone levels (E2, P4) during the mid-luteal phase and IVF outcomes (biochemical and clinical pregnancy).
Eligibility criteria
Qualifiers
Participating in Assisted Reproduction Treatment
Having infertility
Having regular menstrual cycles
Embryo transfer of euploid embryos
Disqualifiers
Uterine pathologies
Endometrial Bacterial infections
Active endometrial inflammation
Polycystic ovary syndrome
Trial design
Treatments tested in this trial
- Platelet rich plasma (PRP)
Treatment groups
50 Participants
are divided into 1 treatment groupLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Nadezhda Women's Health HospitalRecruiting1330, Sofia, Sofia
Bulgaria
BulgariaSponsors and collaborators
Source ClinicalTrials.gov